Article ID | Journal | Published Year | Pages | File Type |
---|---|---|---|---|
2139978 | Leukemia Research | 2006 | 12 Pages |
Abstract
We developed and tested a potent hexameric Fas agonist, termed MegaFasL, for its cytotoxic effects on a panel of human haematopoietic malignant cells and healthy human haematopoietic progenitor cells (CD34+CD38low). Results demonstrated that MegaFasL induced apoptosis in cell lines and primary cells representing multiple myeloma (MM), acute myeloid leukaemia (AML), acute lymphoblastic leukaemia (ALL) and Burkitt's lymphoma. Cells from a chronic myeloid leukaemia (CML) line and from patients with chronic lymphocytic leukaemia (CLL) were resistant. Furthermore, CD34+CD38low progenitor cells were also resistant to MegaFasL. The data indicate that MegaFasL could be a highly efficient therapeutic agent ex vivo or potentially in vivo.
Keywords
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Cancer Research
Authors
Peter Greaney, Aimable Nahimana, Lucienne Lagopoulos, Anne-Lise Etter, Dominique Aubry, Antoine Attinger, Nicola Beltraminelli, Boris Huni, Isabelle Bassi, Bernard Sordat, Stéphane Demotz, Marc Dupuis, Michel A. Duchosal,